RxDoctor Payments Data

Pei Ann Kong, MD

Internal Medicine · Upland, PANPI 1912999798

Payments from drug & device makers

$2,047in general payments, 2019–2025

Across 120 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$620
  • AbbVie$311
  • Lilly USA, LLC$212
  • Pfizer$151
  • AstraZeneca$127
  • GSK$112
  • plus $513 from 14 others

What the payments were for

  • Food & beverage$2,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,047 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,215
Medicare patients
157
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$65,340
JardianceEmpagliflozin87$62,319
EliquisApixaban40$22,505
XareltoRivaroxaban24$21,695
RybelsusSemaglutide12$11,107
FarxigaDapagliflozin Propanediol14$8,919
JanuviaSitagliptin Phosphate16$7,807
MyrbetriqMirabegron16$6,595
Atorvastatin Calcium427$6,324
Albuterol Sulfate HfaAlbuterol Sulfate158$5,227
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$4,737
Rosuvastatin Calcium222$3,506
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,306
Amlodipine Besylate354$2,491
Levothyroxine Sodium184$2,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$620$76,44786 claims
Boehringer IngelheimJardiance$88$62,31987 claims
PfizerEliquis$151$22,50540 claims
Johnson & JohnsonXarelto$44$21,69524 claims
AstraZenecaFarxiga$127$8,91914 claims
MerckJanuvia$30$7,80716 claims
Astellas Pharma US IncMyrbetriq$16$6,59516 claims
AbbVieSynthroid$311$1,43118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Upland

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →